Outcomes of treatment for low-risk stage II to III gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2018

Stage II results
	Number of patients	Number of remissions
	38	38 (100 percent)
Low-risk	22	22 (100 percent)
Initial therapy		17 (77.3 percent)
Sequential MTX/ActD		16
Combination chemotherapy*		1
Resistant therapy	5	5 (22.7 percent)
Combination chemotherapy*		4
Salvage therapy^¶		1
Stage III results
	Number of patients	Number of remissions
	233	230 (98.7 percent)
Low-risk	156	156 (100 percent)
Initial therapy		122 (78.2 percent)
Sequential MTX/ActD		115
Combination chemotherapy^Δ		7
Resistant therapy	34	34 (21.8 percent)
Sequential MTX/ActD		1
Combination chemotherapy^Δ		33

Two patients alive with disease; one death.

MTX: methotrexate; ActD: actinomycin D; MAC: methotrexate, actinomycin D, cyclophosphamide; EMA: etoposide, methotrexate, actinomycin D; CO: cyclophosphamide plus vincristine; EP: etoposide, cisplatin.
* MAC, EMA, EMA/CO.
¶ EMA/CO, EMA/EP.
Δ MAC, EMA, EMA/CO.

Graphic 97197 Version 4.0

خرید پکیج

Outcomes of treatment for low-risk stage II to III gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2018